Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frevecitinib in Severe Asthma
NCT07532265Phase 2Recruiting
- Sponsor
- Kinaset Therapeutics
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of frevecitinib in severe asthma, sponsored by Kinaset Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
frevecitinib
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT07532265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532265.